Evaluation of flaxseed effects on non-alcoholic fatty liver disease (NAFLD) in  rabbits submitted to a hypercholesterolemic diet by Caroline Tatim Saad et al.
Functional Foods in Health and Disease 2014; 4(10):442-450                                                             Page 442 of 450 
 
Research Article                       Open Access 
 
Evaluation of flaxseed effects on non-alcoholic fatty liver disease (NAFLD) in 
rabbits submitted to a hypercholesterolemic diet 
 
Caroline Tatim Saad
1, Dalton Bertolim Précoma
2, Alexandre Bueno Merlini
3, Sérgio 
Ossamu Ioshii
4, Ana Flávia Champoski
5 
 
1State University of Ponta Grossa,  Paraná,  Brazil; 
2Pontifical  Catholic University  of Paraná, 
Paraná, Brazil; 
3Medical Student in State University of Ponta Grossa, Paraná, Brazil; 
4Pontifical 
Catholic University of Paraná, Paraná, Brazil; 
5Pontifical Catholic University of Paraná, Paraná, 
Brazil 
 
*Corresponding  author:  Alexandre  Bueno  Merlini,  PhD,  Department  of  Medicine,  State 
University of Ponta Grossa. Av. Balduíno Taques, 1441, ap.43 Centro, `Ponta Grossa, Paraná 84-
010-050, Brazil 
 
Submission date: June 26, 2014; Acceptance date: October 27, 2014; Publication date:  
October 27, 2014 
 
 
ABSTRACT 
Background: The aim of the present study is to evaluate the role of flaxseed in non-alcoholic 
fatty liver disease, as well as on the lipid profile in rabbits submitted to hypercholesterolemic 
diet. 
 
Subject  and  Methods:  32  male  rabbits,  weighing  approximately  1.5kg  and  averaging  four 
months of age, were distributed into three groups. Group 1 received standard food plus 0.5% of 
cholesterol from dried egg, during 8 weeks. Group 2 obtained the same diet in the first 4 weeks, 
and 8mg/kg of ground flaxseed was added in the remaining weeks. Lastly, group 3 was fed with 
the previous group’s increased diet throughout the entire period. In the follow-up, the animals 
were  euthanized,  and  liver  blades  were  prepared  to  evaluate  the  histopathologic  study.  The 
evaluation  score  of  NAFLD  (ESN),  as  well  as  plasma  levels  of  total  cholesterol,  LDL-
cholesterol, HDL-cholesterol, triglycerides and body weight, were all determined. 
 
Results:  Increased levels of total cholesterol were obtained in both groups, with the smallest 
variation  found  in  G3  (p=0.002).  This  variation  was  also  found  when  the  levels  of  LDL-
cholesterol were assessed (p=0.001). There was a reduction of triglyceride levels at the end of 
the study in G3 (p=0.008). A variation was noticed between the ESN groups, but the induced 
reduction was not statistically significant.  
 
Conclusion:  Further  studies  are  necessary,  in  order  to  elucidate  the  effects  of  flaxseed  in 
NAFLD as well as in diseases that have risk factors for the development of the disease. Functional Foods in Health and Disease 2014; 4(10):442-450                                                             Page 443 of 450 
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BACKGROUND 
A distinct group of liver diseases is related to metabolism disorders, either acquired or inherited. 
The non-alcoholic fatty liver disease (NAFLD) is the most common acquired metabolic disorder 
and it is characterized by the presence of hepatic steatosis in individuals who do not consume 
alcohol,  or  do  so  in  very  small  quantities  (less  than  20g  of  ethanol  per  day)  [1-3].  The 
understanding of the epidemiology and natural history of NAFLD has increased; it is the most 
common form of chronic liver disease in the Western world, and it’s becoming more important 
in other parts of the world [4].
 
NAFLD  includes  simple hepatic  steatosis,  steatosis  accompanied  by  minor,  non-specific 
inflammation, and non-alcoholic steatohepatitis (NASH) [1]. Bland steatosis remains stable for a 
number  of  years  and  will  probably  never  progress,  in  many  cases.  In  contrast,  NASH  is  a 
condition in which there is hepatocyte injury that may progress to cirrhosis in 10% to 20% of 
cases. The main components of NASH are hepatocyte ballooning, lobular inflammation, and 
steatosis. With the progress of the disease, fibrosis occurs [5].
 
NASH affects men and women equally, and the condition is strongly associated with obesity 
and other components of the metabolic syndrome (MS), such as dyslipidemia, hyperinsulinemia, 
and insulin resistance. It is estimated that more than 70% of obese individuals have some form of 
NAFLD, and the epidemic of obesity heightens the concern that it will increase in prevalence 
[4,6].
 
Because of the association between NASH and the MS, cardiovascular disease is a frequent 
cause of death in patients with NASH. The goal of treating individuals with NASH is to reverse 
the steatosis and prevent cirrhosis [7]. The current management strategy seeks to correct the 
underlying risk factors, such as obesity and hyperlipidemia, and to treat insulin resistance [8].
 
Clinical trials and experimental models have shown that the inclusion of functional foods in 
the  diet  promotes  improvements  in  risk  factors  linked  to  cardiovascular  diseases,  such  as 
hypercholesterolemia [9]. Currently, many foods with functional properties have been considered 
as  a prevention method  for  atherosclerotic lesions  and other cardiovascular diseases,  mainly 
because their compositions contain, for example, high percentages of n-3 fatty acids, plant sterol 
esters, and vegetable fiber [10,11].
 
The flaxseed (Linum usitatissimun L.) has been considered a functional ingredient of great 
importance  by  the  American  Heart  Association.  The  importance  is  due  to  its  functional 
combinations, such as linolenic acid, lignans, and soluble fibers that are potentially beneficial to 
our health, mainly to the heart [12].
 
The active component of flaxseed (lignans - secoisolariciresinol diglucoside - SDG) has 
significant  antioxidant effects  resulting from  the inhibition  of the DNA's divisions and lipid 
peroxidation, as well as a decreased production of reactive oxygen species. Several clinical and 
experimental trials provide evidence of the numerous cardioprotective effects of lignans [3]. 
Since  NASH  is  strongly  associated  with  metabolic  syndrome,  as  well  as  cardiovascular 
diseases, the study of functional properties of flaxseed is of extreme importance and enrichment 
for the scientific community and the population [7]. Functional Foods in Health and Disease 2014; 4(10):442-450                                                             Page 444 of 450 
 
SUBJECT AND METHODS 
Thirty-two white adult male rabbits (New Zealand), averaging four months of age, were selected 
for this study. Animals were handled in compliance with the Guiding Principles in the Care and 
Use of Animals, and protocol approval was obtained from the Pontifical Catholic University 
Animal Research Committee. The animals were divided into three groups, for a period of eight 
weeks: group I (GI), the control group, 11 rabbits; group II (GII), 10 rabbits, fed throughout  half 
of the period with flaxseed; group III (GIII), 11 rabbits, fed throughout the entire study with 
flaxseed. During the 56-day study, the animals from GI were fed with a specific diet (Nuvilab®), 
plus  1%  cholesterol  from  lyophilized  egg.  This  diet  (Nuvilab®)  does  not  alter  the  lipid 
metabolism of the animals. GII received, from the fifth week onwards, besides the standard diet, 
8mg/kg of flaxseed. And GIII was fed with GII’s second diet for the entire the period. On day 
56,  the  animals  were  submitted  to  liver  resection.  Anesthesia  was  induced  with  ketamine 
(Vetarnacol®, König: 30mg/kg) and intramuscular xylazine (Coopazine®; Coopers: 6mg/kg). 
After the procedure, the rabbits were sacrificed via a lethal barbiturate dosage.  
 
Blood chemistry 
Blood  samples  were  collected  on  the  first  day  of  the  experiment,  and  immediately  before 
sacrifice via cardiac puncture. The laboratory assessment included: total cholesterol (TC), high-
density  lipoprotein  cholesterol  (HDL-C),  low-density  protein  cholesterol  (LDL-C),  and 
triglycerides (TGL). Measurements were taken using an automated system (Abbott Architect 
ci8200; Abbott Laboratories, Abbott Park, II). 
 
Histological Analysis 
The liver segments were removed and fixed with 10% formaldehyde, buffered with phosphate 
(pH=7.6), and then embedded with paraffin. Three slices with two histological sections were 
prepared, one with a left medial lobe liver sample, and one with a quadrate lobe liver sample. 
One  slice  was  stained  with  hematoxylin  and  eosin  (HE),  and  two  slices  were  stained  with 
periodic  acid  Schiff  (PAS)  and  Gomori’s  trichrome.  The  slices  were  analyzed  blindly  for 
steatosis,  lobe  inflammation,  hepatic  cell  balonization,  and  fibrosis  status  according  to  the 
histological score system for NAFLD, using a five-head Olympus® BX 40 microscope.  
 
Statistical Analysis 
Categorical variables were expressed as percentages, and continuous variables were expressed as 
an  average  ±  standard  deviation  (SD).  The  Shapiro-Wilks  test  was  used  for  testing  sample 
normality. For quantitative parameters, the student t-test and Mann-Whitney nonparametric test 
were used for comparison between groups. Statistical significance was indicated by a value of p 
<  0.05.  For  multiple  comparisons  through  Fisher’s  exact  test  the  level  of  significance  was 
corrected by Bonferroni. Therefore, for these comparisons, statistical significance was indicated 
by a value of p < 0.017. Analyses were performed using Statistica/W version 5.1 (StatSoft, 
Tulsa, OK). 
   
RESULTS 
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Animal weight gain did not differ among the groups between baseline and euthanasia (Table 1), 
However,  when  individually  analyzed,  there  was  a  significant  difference  between  the  basal 
weight and euthanasia’s weight (p<0,001). In relation to the lipid profile, a significant difference 
between the groups was found when analyzing the total cholesterol, LDL-cholesterol and HDL-
cholesterol (Table 2). 
 
Table 1. Weight variation between groups 
 
Weight  Group  n  Mean ± 
SD 
p 
Basal (B)  GI 
GII 
GIII 
11 
10 
11 
1882±267 
1876±209 
2053±345 
 
0,268 
Euthanasia (E)  GI 
GII 
GIII 
11 
10 
11 
2975±165 
3154±268 
3080±380 
 
0,367 
Difference (E-B)  GI 
GII 
GIII 
11 
10 
11 
1120±277 
1280±204 
1015±244 
 
0,071 
 
Table 2. Lipid profile at baseline (T0) and euthanasia (T8) 
 
Variable 
 
G1 – T0 
Mean ± SD 
G1-T8 
Mean ± SD 
G2 – T0 
Mean ± SD 
G2 – T8 
Mean ± SD 
G3 – T0 
Mean ± SD 
G3 – T8 
Mean ± SD 
p value 
G1xG2xG3 
 
 
Total 
cholesterol 
 
75,8 ± 36,7 
 
642,3 ± 
392,4 
 
Variation 
G1 
566,5 ± 
372,7 
73,5 ± 25,3  731,6 ± 
258,9 
 
Variation 
G2 
658,1 ± 
250,4 
61,7 ± 14,9 
 
 
321,7 ± 
215,3 
 
Variation 
G3 
260 ± 208,6 
 
T0: 0,442 
T8: 0,009 
 
 
0,009 
 
 
 
 
 
LDL-
cholesterol 
34,8 ± 33,7  605,4 ± 
390,1 
 
Variation 
G1 
570,6 ± 
370,2 
30,6 ±21,7  694,8 ± 
255,1 
 
Variation 
G2 
664,2 ± 246 
 
12,8 ± 6,6 
 
 
294 ± 211,4 
 
 
Variation 
G3 
281,1 ± 
206,9 
T0:0,085 
T8:0,01 
 
 
0,011 
 
 
 
 
HDL-
cholesterol 
21,3 ± 9,3  23,7 ± 8,8 
 
Variation 
G1 
2,5 ± 11,7 
20,3 ± 4,7  19,1 ± 4,6 
 
Variation 
G2 
-1,2 ± 7,8 
24,4 ± 5,8 
 
 
15 ± 3,8 
 
Variation 
G3 
-9,4 ± 6,6 
T0:0,0381 
T8:0,01 
 
 
0,014 
 
 
Triglycerides 
98,5 ± 40,6  65,6 ± 26,2 
 
Variation 
G1 
-32,8 ± 48,8 
112,2 ± 31,2  88,5 ± 37,3 
 
Variation 
G2 
-23,7 ± 45,4 
161 ± 88,1 
 
 
63,8 ± 31,9 
 
Variation 
G3 
-97,2 ± 98,3 
T0:0,050 
T8:0,166 
 
0,166 
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Histological Analysis 
The non-alcoholic fatty liver disease was successfully induced in all groups. However, there was 
no statistically significant difference between them. The frequency of the histologic findings is 
showed in Table 3.  
 
Table 3. Results of histological analysis 
 
Item  Definition  S
core 
G1  G2  G3 
Steatosis grade  < 5% 
5 to 33% 
33 to 66% 
> 66% 
0 
1 
2 
3 
27,27% 
63,64% 
9,09% 
0 
10% 
70% 
20% 
0 
36,36% 
63,64% 
0 
0 
Fibrosis stage  None 
Perisinusoidal or 
periportal 
0 
1 
81,82% 
18,18% 
100% 
0 
 
81,82% 
18,18% 
Lobular 
inflammation 
No foci 
<2 foci per 200x field 
2-4 foci per 200x 
field 
>4 foci per 200x field 
0 
1 
2 
3 
90,91% 
9,09% 
0 
0 
70% 
30% 
0 
0 
72,73% 
27,27% 
0 
0 
Hepatocellular 
ballooning 
None 
Few balloon cells 
Many cells/prominent 
ballooning 
0 
1 
2 
0 
72,73% 
27,27% 
0 
60% 
40% 
0 
36,36% 
63,64% 
 
 
DISCUSSION  
NAFLD is now the most common liver disease in the United States, and possibly worldwide. 
Furthermore, the number of affected patients is growing rapidly, and the disease has reached 
epidemic  proportions.  It  is  now  believed  to  be  the  hepatic  manifestation  of  the  metabolic 
syndrome (MS), and an independent predictor of cardiovascular morbidity and mortality [4].
 
Although not every variant of NAFLD is associated with insulin resistance and the MS, its 
main component, the NASH, is now considered a clinical entity with characteristics that allow 
defining it as  a disease [7]. Its  pathogenesis, although not  yet  fully elucidated, includes  the 
accumulation of excess lipid in hepatocytes by insulin resistance, and the oxidative stress causing 
lipid peroxidation, which activates pro-inflammatory cytokines [1]. 
There is still no specific pharmacological treatment for NAFLD or NASH. Most drugs are 
used to mitigate some of the symptoms or treat comorbidities, such as those present in the MS 
(obesity,  insulin  resistance  or  DM2,  hypertension,  dyslipidemias  -  particularly 
hypertriglyceridemia). The therapeutic options currently employed improve upon the laboratory 
abnormalities  associated  with  NAFLD,  but  it  proved  ineffective  in  reducing  the  degree  of 
steatosis, perhaps due to the lack of randomized controlled trials (RCT's) [9].
 
Flaxseed is considered to be one of the richest sources of Ω-3 α-linolenic fatty acids, and 
therefore  the  richest  source  of  mammalian  lignan  precursors  such  as  secoisolariciresinol Functional Foods in Health and Disease 2014; 4(10):442-450                                                             Page 447 of 450 
 
diglucoside  (SDG),  pinoresinol,  matairesinol,  and  lariciresinol,  among  others.  Due  to  the 
antioxidant, anti-proliferative, anti-estrogenic, anti-aromatase and anti-angiogenic activities, its 
effect on various diseases has been studied, including on liver diseases such as NAFLD [12,13].
 
In previous studies, we found that SDG reduces the high lipid levels in rats, which was 
induced through a hypercholesterolemic diet. In a clinical trial, Fukumitsu et al. concluded that 
when compared to  a placebo, the administration of 100mg of SDG resulted in  a significant 
reduction of the LDL/HLD cholesterol ratio, and of the levels of alanine aminotransferase and 
gamma-glutamyl-transpeptidade, these being typically increased in fractions in NAFLD [14].
 
In  this  study  we  observed  that  there  was  a  marked  increase  in  total  cholesterol  levels 
throughout all groups, and in the G3 (diet with flaxseed supplementation since the beginning), 
this variation was small compared to other groups. This same observation was made in relation 
to LDL. 
In a double-blind, randomized, controlled study, guided by Wu et al., it was noted that 12-
week supplementation with flaxseed, within a program of changing styles and habits of life, 
significantly reduced the number of MS’s components, including weight, waist circumference, 
total cholesterol, LDL cholesterol, apolipoproteins B and E, and arterial pressure [15]. 
Regarding HDL, there was no significant change between groups, but we observed an HDL 
decrease in in G3 at the end of the study. A clinical trial organized by Bloedon and colleagues 
found that, in males, there was a 16% reduction in HDL−a follow-up of cholesterol in 5 weeks, 
and 9% when measured in 10 weeks [16]. 
 When we analyzed the triglycerides, we found a significant reduction in levels of G3. 
The role of the flaxseed in triglyceride levels, according to the literature, is controversial. 
Some studies, such as a meta-analysis by Pan et al., did not find significant changes in plasma 
levels of TG.84. Meanwhile, a research with a follow-up of 64 weeks in birds, led by Cherian et 
al., said that a diet with 10% of flaxseed significantly decreased hepatic and plasma levels of 
triglycerides [17]. 
 The NAFLD activity score (DAS), which corresponds to the unweighted sum of scores of 
steatosis,  lobular  inflammation  and  hepatocyte  ballooning,  is  appropriately  related  with  the 
presence of NASH when ≥ 5, with the absence when ≤ 2, and had no value discriminating 
between 3 and 4 in the study for its validation. 
Although  there  was  a  variation  between  groups  of  DAS  as  well  as  the  individual 
components of the DAS, this reduction was not statistically significant, showing that flaxseed 
was not able to reduce the degree of steatosis in rabbits submitted to hypercholesterolemic diet to 
0.5% dried egg. This may be due to sample size, even  with the duration of the study. 
 The data in this study showed positive effects of flaxseed in the correction of lipid disorders 
associated with NAFLD, but was not effective in reducing hepatic steatosis. Human studies show 
that the improvement in steatosis is associated with a previous improvement of lipid disorders 
and other disorders associated with MS, as well as reducing conditions that lead to oxidative 
stress. This shows the need for longer studies and larger samples. 
In the study by Cherian et al., it was noted that the intervention with flaxseed reduced the 
plasma and hepatic lipid content, the accumulation of triglycerides in the liver (steatosis), the 
total  number  of  lipid  vacuoles,  and  the  number  of  hepatocytes  with  75%  or  more  lipid Functional Foods in Health and Disease 2014; 4(10):442-450                                                             Page 448 of 450 
 
infiltration. However, as already mentioned, the follow-up study took 64 weeks, and this may be 
the cause of the difference in results [18]. 
In other studies, such as Lirussi et al., the assessment of liver function showed an increased 
activity of gamma-glutamyl transpeptidase, but no change in aminotransferases. These studies 
affirm the potential of flaxseed as a protector of the progression of liver damage, but not as 
treatment of DHGNA [19]. 
There are not many studies analyzing NAFLD  in rabbits.  In this study, the model used 
followed the line of the supervisor, and may contribute to the development of a standard model 
of NAFLD in experimental rabbits. Given the biochemical, hematological and histopathological 
results obtained, we can think about a correlation of applications of flaxseed in humans, since the 
pathogenesis and mechanism of inflammatory injury in the two species are the same. However, 
very few studies reported this association in humans, and most of them using rodents, due to the 
ease of production. 
 Among those who already  carried out  similar studies,  we have Sturzeneker et  al.,  who 
evaluated the role of olmesartan, an angiotensin receptor blocker-II, in the course of NAFLD. 
The results showed that, after NAFLD being installed, this drug prevents the development of 
fibrosis and lobular inflammation, and reduced the risk of NASH. However, the drug was not 
effective in preventing steatosis [20]. 
Another study by Prim et al. found that the intake of flaxseed lowered LDL-cholesterol and 
total  cholesterol.  However,  there  was  no  significant  difference  in  the  presence  or  degree  of 
atherosclerotic lesions in the group that received the seed and the group that did not [21]. 
 
CONCLUSION 
According to what was seen, when we compare the results obtained in this study with those 
found  in  medical  literature,  we  find  that  they  are  similar,  since  both  managed  to  obtain  an 
improvement in lipid profile (triglycerides, total cholesterol and LDL-cholesterol) and to prevent 
the progression of disease nonalcoholic fatty liver. 
Further studies are necessary, in order to elucidate the effects of flaxseed in NAFLD as well 
as in diseases that have risk factors for the development of the disease. 
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